Compare DSGX & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSGX | DNTH |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.9B |
| IPO Year | 1999 | 2018 |
| Metric | DSGX | DNTH |
|---|---|---|
| Price | $76.22 | $106.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $105.22 | ★ $121.00 |
| AVG Volume (30 Days) | 518.1K | ★ 544.6K |
| Earning Date | 06-03-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | $12.05 | N/A |
| Revenue Next Year | N/A | $29.48 |
| P/E Ratio | $37.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $62.56 | $32.28 |
| 52 Week High | $105.24 | $117.88 |
| Indicator | DSGX | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 35.35 | 44.50 |
| Support Level | $69.53 | $101.19 |
| Resistance Level | $74.96 | $107.99 |
| Average True Range (ATR) | 2.75 | 4.59 |
| MACD | -0.99 | -0.85 |
| Stochastic Oscillator | 5.72 | 26.26 |
Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.